Metsera Faces Regulatory and Bidding Setbacks

about 1 month ago

Tom Keane

"There are. There are. Okay, so we talked about it earlier um weight loss drug startup Metsera that's sticker M um M MTSR their shares have been taking a hit down 15%. The basic thing is that the bidding war between Novo Nordisk and Fizer, it's ended, right? So Fi Novo decided, you know what, we're not going to raise our offer again. Um, another reason Novo stepped aside is because Meter said it got a call from the FTC that flagged potential regulatory risks um with the structure of the deal."

The speaker highlights that Metsera (MTSR) shares are down 15% amid a failed bidding war between Novo Nordisk and Pfizer, due in part to regulatory concerns flagged by the FTC, suggesting caution for investors.

Related Stocks